Dr. Helen Kent Chew, MD

Dr. Chew practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Chew's NPI, 1801870142, was assigned on November 30, 2005. Dr. Chew graduated from The University of Texas Health Science Center at San Antonio in 1991. Dr. Chew holds California license A73302.

Dr. Chew's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Chew's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Chew to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chew practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Chew's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Chew is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Chew's licenses on file in 2 states: California and Texas.

Dmand AI lists breast cancer, chronic leukemia, lung cancer, lymphoma and prostate cancer among the conditions Dr. Chew treats.

CMS data shows 612 Medicare services from Dr. Chew across 7 procedure codes in 2024, for 205 Medicare patients. Medicare paid $33,133 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 205 Medicare patients who saw Dr. Chew in 2024. The largest group is 65 to 74, with 101 patients. 75% of them have cancer, and 70% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chew's median patient age at 65, with 85% women.

In 2024, Dr. Chew wrote 446 Medicare Part D claims for 81 patients. 67% of them were for generic drugs. CMS names the drug for 375 of them, across 10 drugs with 11 or more claims each, at $1,810,079 in total drug cost. In 2023, CMS named 297 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Chew for performance year 2024, reported as part of a group. Dr. Chew accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chew as offering telehealth.

Dmand AI links 51 papers to Dr. Chew, published from 2006 to 2022. 2014 was the busiest year, with 7. The most frequent topics are Breast Neoplasms, California and Antineoplastic Combined Chemotherapy Protocols. Dr. Chew has published most often in J Clin Oncol. Dr. Chew's most frequent co-authors are Gabriel N. Hortobagyi, MD, William J. Gradishar, MD and Joanne E. Mortimer, MD.

Dmand AI links Dr. Chew to 10 clinical trials, 4 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Breast Carcinoma In Situ. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 27 general payments to Dr. Chew from 8 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 56% of the total. Novartis Pharmaceuticals Corporation paid the most, $4,441.

Dr. Chew graduated from The University of Texas Health Science Center at San Antonio in 1991.

Dr. Chew is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.